Creative Planning
CTKB icon

Creative Planning’s Cytek Biosciences CTKB Stock Holding History

Creative Planning’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Sell
62,555
-27,382
-30% -$117K ﹤0.01% 3631
2026
Q1 		$393K Sell
89,937
-31,272
-26% -$148K ﹤0.01% 3209
2025
Q4 		$612K Buy
121,209
+12,578
+12% +$58.4K ﹤0.01% 2663
2025
Q3 		$377K Buy
108,631
+52,954
+95% +$199K ﹤0.01% 2965
2025
Q2 		$189K Buy
55,677
+45,652
+455% +$152K ﹤0.01% 3243
2025
Q1 		$40.2K Buy
+10,025
New +$52K ﹤0.01% 3360

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Creative Planning's CTKB Position: Q2 2026 in Review

Creative Planning reduced its Cytek Biosciences (CTKB) stake by 30% in Q2 2026, selling an estimated $117K and leaving 62,555 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #3631.

Creative Planning first reported a position in CTKB in Q1 2025 and has held it in 6 quarters since. The position peaked at $612K in Q4 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Creative Planning held 62,555 shares of Cytek Biosciences worth $277K as of Q2 2026.
  • Creative Planning sold 27,382 Cytek Biosciences shares in Q2 2026, an estimated $117K.
  • Cytek Biosciences made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3631 holding.
  • Creative Planning first reported a position in Cytek Biosciences in Q1 2025 and has held it in 6 quarters since.
  • Creative Planning's Cytek Biosciences position peaked at $612K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.